Efficacy and Safety Of Sofosbuvir Plus Ribavirin In Chronic Hepatitis C Egyptian Patients with Child class A and B (comparative study).

Many treatment regimens are available for treatment of chronic hepatitis c in different stages of the disease , include all oral direct acting antiviral agents (DAA) . Aim:-The aim of our work was to compare the efficacy and safety of sofosbuvir and ribavirin in treatment patients with child class A and B in chronically infected HCV Egyptian patients. Patients and Methods:- A total number of 132 chronic hepatitis C Egyptian patients were divided into two groups . Group 1 included 56 patients with child class A while group 2 included 76 patients with early child class B (score 7) . All patients were given sofosbuvir 400 mg once daily and weight based ribavirin (1200 mg daily if weight >75 kg or 1000 mg daily if weight ? 75kg ) for 6 months. Inclusion and exclusion criteria were according to Egypt HCV Management Guidance at September , 2014 . Results:- By the end of treatment , 93.75% of the patients had achieved SVR . SVR was 95 % in patients with child A and 92.6 % at child B group . The most common adverse effects were fatigue , anemia , jaundice, headache , insomnia , but 7.6 % of the patients had stopped the treatment due to severe complications. Conclusion:- The findings from the present study suggest that 24 weeks of all-oral regimen of sofosbuvir plus ribavirin is an efficacious and well tolerated treatment in patients with chronic HCV infection and non inferior to currently available treatment options based on the proportion of patients who had achieved SVR. Twenty four weeks of all-oral regimen of sofosbuvir plus ribavirin is an efficacious and well tolerated treatment in patients with chronic HCV infection and non inferior to currently available treatment options .